CA1156953A
(en)
|
1979-06-08 |
1983-11-15 |
Michael A. Kessick |
Lime addition to heavy crude oils prior to coking
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5262177A
(en)
|
1986-02-07 |
1993-11-16 |
Oncogen |
Recombinant viruses encoding the human melanoma-associated antigen
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5171665A
(en)
|
1989-04-17 |
1992-12-15 |
Oncogen |
Monoclonal antibody to novel antigen associated with human tumors
|
EP0474727B1
(en)
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extracellular domain
|
US5204253A
(en)
|
1990-05-29 |
1993-04-20 |
E. I. Du Pont De Nemours And Company |
Method and apparatus for introducing biological substances into living cells
|
US5830702A
(en)
|
1990-10-31 |
1998-11-03 |
The Trustees Of The University Of Pennsylvania |
Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
FR2686896B1
(fr)
|
1992-01-31 |
1995-01-06 |
Pasteur Institut |
Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
|
US5633234A
(en)
|
1993-01-22 |
1997-05-27 |
The Johns Hopkins University |
Lysosomal targeting of immunogens
|
US5679647A
(en)
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
US5804566A
(en)
|
1993-08-26 |
1998-09-08 |
The Regents Of The University Of California |
Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
US7662396B2
(en)
*
|
2001-03-26 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
US7794729B2
(en)
|
1994-11-08 |
2010-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for immunotherapy of cancer
|
US6051237A
(en)
|
1994-11-08 |
2000-04-18 |
The Trustees Of The University Of Pennsylvania |
Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
|
US20070264279A1
(en)
*
|
1994-11-08 |
2007-11-15 |
Claudia Gravekamp |
Compositions and methods comprising a MAGE-b antigen
|
US7820180B2
(en)
|
2004-09-24 |
2010-10-26 |
The Trustees Of The University Of Pennsylvania |
Listeria-based and LLO-based vaccines
|
US8114414B2
(en)
*
|
1994-11-08 |
2012-02-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical cancer
|
US5736524A
(en)
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
US5681570A
(en)
|
1995-01-12 |
1997-10-28 |
Connaught Laboratories Limited |
Immunogenic conjugate molecules
|
US6017705A
(en)
|
1995-03-14 |
2000-01-25 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
|
US5877159A
(en)
|
1995-05-03 |
1999-03-02 |
University Of Maryland At Baltimore |
Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
|
US5922687A
(en)
|
1995-05-04 |
1999-07-13 |
Board Of Trustees Of The Leland Stanford Junior University |
Intracellular delivery of nucleic acids using pressure
|
CA2223103A1
(en)
|
1995-06-06 |
1996-12-12 |
Isis Pharmaceuticals Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
ATE312934T1
(de)
|
1995-06-07 |
2005-12-15 |
Univ Washington |
Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
|
US5643599A
(en)
|
1995-06-07 |
1997-07-01 |
President And Fellows Of Harvard College |
Intracellular delivery of macromolecules
|
US5985662A
(en)
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
US5824538A
(en)
|
1995-09-06 |
1998-10-20 |
The United States Of America As Represented By The Secretary Of The Army |
Shigella vector for delivering DNA to a mammalian cell
|
US5922583A
(en)
*
|
1995-10-17 |
1999-07-13 |
Biostar Inc. |
Methods for production of recombinant plasmids
|
DE19541450C2
(de)
|
1995-11-07 |
1997-10-02 |
Gsf Forschungszentrum Umwelt |
Genkonstrukt und dessen Verwendung
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
US6740506B2
(en)
*
|
1995-12-07 |
2004-05-25 |
Diversa Corporation |
End selection in directed evolution
|
EP0960204A4
(en)
|
1996-07-26 |
2002-01-23 |
Sloan Kettering Inst Cancer |
METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
|
US5858682A
(en)
|
1996-08-02 |
1999-01-12 |
Pharmingen |
E2A/pbx1 fusion protein specific monoclonal antibodies
|
WO1998012332A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6562217B1
(en)
*
|
1997-04-17 |
2003-05-13 |
Sekisui Chemical Co., Ltd. |
Method and device for manufacturing conductive particles
|
JP2002513287A
(ja)
|
1997-04-18 |
2002-05-08 |
ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー(ゲー ベー エフ) |
サルモネラ株
|
US6833135B1
(en)
|
1997-08-06 |
2004-12-21 |
Laboratorio Medinfar Produtos Farmaceuticos, Lda. |
DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
|
EP0902086A1
(en)
|
1997-08-22 |
1999-03-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Tuberculosis vaccine
|
US20040013685A1
(en)
|
1997-11-10 |
2004-01-22 |
Peter Andersen |
Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
|
US6099848A
(en)
*
|
1997-11-18 |
2000-08-08 |
The Trustees Of The University Of Pennsylvania |
Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
US6004815A
(en)
|
1998-08-13 |
1999-12-21 |
The Regents Of The University Of California |
Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
|
JP2002531466A
(ja)
|
1998-12-01 |
2002-09-24 |
プロテイン デザイン ラブス, インコーポレイテッド |
γ−インターフェロンに対するヒト化抗体
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
WO2000049158A2
(en)
|
1999-02-18 |
2000-08-24 |
Compugen Ltd. |
Psa and klk-2 splicing variants
|
CA2393688A1
(en)
|
1999-12-09 |
2001-06-14 |
Chiron Corporation |
Method for administering a cytokine to the central nervous system and the lymphatic system
|
US9012141B2
(en)
*
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
US6855320B2
(en)
*
|
2000-03-29 |
2005-02-15 |
The Trustees Of The University Of Pennsylvania |
Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
|
CA2404164A1
(en)
|
2000-03-29 |
2001-10-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing immunogenicity of antigens
|
WO2001079274A2
(en)
|
2000-04-19 |
2001-10-25 |
Statens Serum Institut |
Tuberculosis antigens and methods of use thereof
|
DE60120712T2
(de)
|
2000-08-11 |
2007-07-19 |
Mount Sinai Hospital, Toronto |
Kallikrein gen
|
US7700344B2
(en)
|
2001-03-26 |
2010-04-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
US8771702B2
(en)
|
2001-03-26 |
2014-07-08 |
The Trustees Of The University Of Pennsylvania |
Non-hemolytic LLO fusion proteins and methods of utilizing same
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
US7432304B2
(en)
|
2001-05-30 |
2008-10-07 |
The Regents Of The University Of Michigan |
Small molecule antagonists of Bcl-2 family proteins
|
FR2825633B1
(fr)
|
2001-06-11 |
2005-12-16 |
Bio Veto Tests Bvt |
Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
|
WO2003065787A2
(en)
|
2002-02-06 |
2003-08-14 |
Johns Hopkins University School Of Medicine |
Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
|
US7425449B2
(en)
|
2002-04-30 |
2008-09-16 |
The Regents Of The University Of California |
Site specific Listeria integration vectors and methods for using the same
|
WO2003102168A1
(en)
|
2002-05-29 |
2003-12-11 |
The Regents Of The University Of California |
Attenuated listeria spp. and methods for using the same
|
EP2243493A1
(en)
|
2002-07-03 |
2010-10-27 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiative composition
|
AU2003259109A1
(en)
|
2002-07-12 |
2004-02-02 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
EP1408048A1
(en)
|
2002-10-07 |
2004-04-14 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
|
MXPA05006828A
(es)
|
2002-12-23 |
2005-09-08 |
Wyeth Corp |
Anticuerpos contra pd-1, y sus usos.
|
JP2006518191A
(ja)
*
|
2003-01-09 |
2006-08-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア |
細菌ワクチンベクターの免疫原性を強化するための組成物、方法、及びキット
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
AU2004246999B2
(en)
|
2003-02-06 |
2010-06-10 |
Aduro Biotech, Inc., |
Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
|
DE10310261A1
(de)
*
|
2003-03-05 |
2004-09-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Identifizierung von Antigen-Epitopen
|
AU2004281834A1
(en)
|
2003-10-15 |
2005-04-28 |
Cerus Corporation |
Listeria-based EphA2 vaccines
|
US20050214318A1
(en)
|
2003-10-23 |
2005-09-29 |
Nmk Research, Llc |
Immunogenic composition and method of developing a vaccine based on fusion protein
|
WO2005061534A2
(en)
|
2003-12-23 |
2005-07-07 |
Statens Serum Institut |
Improved tuberculosis vaccines
|
AU2004314347B2
(en)
|
2003-12-24 |
2011-05-19 |
Aduro Biotech, Inc. |
Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
|
US7842289B2
(en)
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
US7855064B2
(en)
*
|
2004-08-13 |
2010-12-21 |
The Trustees Of The University Of Pennsylvania |
Antibiotic resistance free vaccines and methods for constructing and using same
|
US7858097B2
(en)
|
2004-08-13 |
2010-12-28 |
The Trustees Of The University Of Pennsylvania |
Antibiotic resistance free Listeria strains and methods for constructing and using same
|
CA2577306A1
(en)
*
|
2004-08-13 |
2006-02-16 |
The Trustees Of The University Of Pennsylvania |
Methods for constructing antibiotic resistance free vaccines
|
JP2008516614A
(ja)
|
2004-10-18 |
2008-05-22 |
メディミューン,インコーポレーテッド |
リステリア増殖のための高細胞密度法
|
SI2161336T1
(sl)
|
2005-05-09 |
2013-11-29 |
Ono Pharmaceutical Co., Ltd. |
Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
|
CN100424096C
(zh)
|
2005-06-16 |
2008-10-08 |
华东理工大学 |
含有hiv转导结构域的生存素突变体及制备方法和应用
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
WO2007061848A2
(en)
|
2005-11-17 |
2007-05-31 |
The Trustees Of The University Of Pennsylvania |
Methods for producing, growing, and preserving listeria vaccine vectors
|
RU2006112025A
(ru)
*
|
2005-12-16 |
2007-10-27 |
Хелт Рисерч Инк. (Us) |
Пептиды для стимуляции иммунного ответа против меланомы
|
US7935804B2
(en)
*
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
SI1991263T1
(sl)
*
|
2006-03-01 |
2015-03-31 |
Aduro Biotech |
Listeria spremenjena z inĹľeniringom ter postopki za njenjo uporabo
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
SG175602A1
(en)
|
2006-07-05 |
2011-11-28 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
WO2008008311A1
(en)
|
2006-07-10 |
2008-01-17 |
The Trustees Of The University Of Pennsylvania |
Methods for administering tumor vaccines
|
US8926993B2
(en)
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
WO2008019131A2
(en)
|
2006-08-04 |
2008-02-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating ige-mediated diseases
|
US8268326B2
(en)
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
EP2147092A4
(en)
*
|
2007-04-16 |
2010-06-09 |
Univ Pennsylvania |
ANTIBIOTIC RESISTANCE-FREE LISTERIA TRIBES AND METHOD OF CONSTRUCTING AND USING THEREOF
|
EP2535354B1
(en)
|
2007-06-18 |
2017-01-11 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
WO2009110950A1
(en)
|
2007-12-31 |
2009-09-11 |
The Trustees Of The University Of Pennsylvania |
Attenuated listeria strain and adenovirus strain vaccines and methods of use
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
US9084747B2
(en)
|
2009-11-11 |
2015-07-21 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US20120135033A1
(en)
|
2008-05-19 |
2012-05-31 |
Anu Wallecha |
Multiple delivery system for heterologous antigens
|
CA2724649A1
(en)
|
2008-05-19 |
2009-11-26 |
Anza Therapeutics, Inc. |
Compositions comprising prfa* mutant listeria and methods of use thereof
|
US20110223188A1
(en)
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2011100754A1
(en)
|
2010-02-15 |
2011-08-18 |
The Trustees Of The University Of Pennsylvania |
Live listeria-based vaccines for central nervous system therapy
|
WO2013019906A1
(en)
|
2011-08-01 |
2013-02-07 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
JP2016503655A
(ja)
|
2012-12-27 |
2016-02-08 |
アデュロ バイオテック,インコーポレイテッド |
リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
|